{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:06:45Z","timestamp":1787612805824,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Egyptian Russian University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Mirabegron (MIR) and silodosin (SIL) have recently been combined in a single pill to significantly enhance the effectiveness of treating detrusor hyperactivity with impaired contractility (DHIC), leading to appreciable improvements in symptoms associated with overactive bladder. Additionally, this combination effectively manages lower ureteric stones and improves patient outcomes with no significant side effects, especially in elderly patients. Accordingly, this study introduces two UV techniques for analyzing MIR and SIL in their mixtures (pure and commercial mixtures). These techniques were backed by a one-step salting-out liquid\/liquid extraction (SALLE) procedure for quantifying MIR and SIL in urine samples without matrix interference. The proposed UV techniques succeeded in resolving the superimposed MIR\u2019s and SIL\u2019s UV spectra by employing straightforward mathematical filtration. The UV techniques were Fourier self-deconvolution (FSD) and induced dual-wavelength (IDW) techniques, with linearities of (50\u2013350) \u00b5g\/mL for MIR and (5\u2013100) \u00b5g\/mL for SIL. The applied techniques were verified following the International Council for Harmonisation (ICH) directives and were statistically evaluated against the published technique, with no noteworthy differences found. The applied techniques\u2019 practicality (blueness), whiteness, and greenness were appraised utilizing various metrics. Per the preceding, the applied approaches have been proven to be sustainable, delicate, and appropriate for quality control (QC) testing. Also, backing the applied approaches with the SALLE procedure enables precise monitoring of MIR and SIL in miscellaneous biological fluids with excellent recoveries, presenting an inventive approach for further bioanalytical applications.<\/jats:p>","DOI":"10.1038\/s41598-025-13989-y","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T11:38:28Z","timestamp":1755171508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sustainable UV approaches backed by one step extraction procedure for quantifying the newly released mirabegron and silodosin mixture in urine"],"prefix":"10.1038","volume":"15","author":[{"given":"Ahmed R.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"El\u2011Hanboushy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Darweish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"13989_CR1","first-page":"1","volume":"2","author":"B Chughtai","year":"2016","unstructured":"Chughtai, B. et al. Benign prostatic hyperplasia. Nat. Reviews Disease Primers  2, 1\u201315 (2016).","journal-title":"Nat. Reviews Disease Primers"},{"key":"13989_CR2","doi-asserted-by":"publisher","first-page":"1272592","DOI":"10.3389\/fruro.2023.1272592","volume":"3","author":"X Wang","year":"2023","unstructured":"Wang, X., Yu, Q. & Michel, M. C. Editorial: benign prostatic hyperplasia and overactive bladder: new members of metabolic syndrome. Front. Urol. 3, 1272592 (2023).","journal-title":"Front. Urol."},{"key":"13989_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/ijcp.12176","volume":"67","author":"M Kirby","year":"2013","unstructured":"Kirby, M. et al. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int. J. Clin. Pract. 67, 606\u2013618 (2013).","journal-title":"Int. J. Clin. Pract."},{"key":"13989_CR4","doi-asserted-by":"crossref","unstructured":"Seipel, T. & Schauss, A. G. Lower urinary tract symptoms, overactive bladder syndrome, and urinary incontinence (LUTS, OAB, and UI), textbook of natural medicine. 1533\u20131544. (2020).","DOI":"10.1016\/B978-0-323-43044-9.00194-1"},{"key":"13989_CR5","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.2147\/DDDT.S373659","volume":"16","author":"L Jindan","year":"2022","unstructured":"Jindan, L., Xiao, W. & Liping, X. Evolving role of silodosin for the treatment of urological disorders \u2013 A narrative review. Drug. Des. Devel. Ther. 16, 2861\u20132884 (2022).","journal-title":"Drug. Des. Devel. Ther."},{"key":"13989_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756287212457114","volume":"4","author":"E Sacco","year":"2012","unstructured":"Sacco, E. & Bientinesi, R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther. Adv. Urol. 4, 315\u2013324 (2012).","journal-title":"Ther. Adv. Urol."},{"key":"13989_CR7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"DM Fick","year":"2019","unstructured":"Fick, D. M. et al. American geriatrics society 2019 updated AGS beers criteria\u00ae for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 67, 674\u2013694 (2019).","journal-title":"J. Am. Geriatr. Soc."},{"key":"13989_CR8","first-page":"473","volume":"12","author":"H Cong","year":"2022","unstructured":"Cong, H. et al. Effect of mirabegron combined with silodosin on detrusor hyperactivity with impaired contractile. Chin. J. Rehabilitation Theory Pract. 12, 473\u2013478 (2022).","journal-title":"Chin. J. Rehabilitation Theory Pract."},{"key":"13989_CR9","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s11255-023-03880-y","volume":"56","author":"MS Abdel-Kader","year":"2023","unstructured":"Abdel-Kader, M. S., Sayed, A. M., Sayed, S. M. & AbdelRazek, M. Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones. Int. Urol. Nephrol. 56, 1605\u20131610 (2023).","journal-title":"Int. Urol. Nephrol."},{"key":"13989_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pharma.2023.12.013","volume":"82","author":"S Mishra","year":"2024","unstructured":"Mishra, S., Surekha, N. & Chauhan, A. Development and validation of stability indicating RP-HPLC method for simultaneous Estimation of silodosin and mirabegron in synthetic mixture. Ann. Pharm. Fr. 82, 243\u2013262 (2024).","journal-title":"Ann. Pharm. Fr."},{"key":"13989_CR11","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.52711\/0974-360X.2024.00656","volume":"17","author":"AV Dudhrejiya","year":"2024","unstructured":"Dudhrejiya, A. V. et al. RP-HPLC method development and validation for simultaneous Estimation of mirabegron and silodosin in synthetic mixture. Res. J. Pharm. Technol. 17, 4247\u20134252 (2024).","journal-title":"Res. J. Pharm. Technol."},{"key":"13989_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13065-025-01411-7","volume":"19","author":"KM Badr El-Din","year":"2025","unstructured":"Badr El-Din, K. M., Derayea, S. M., Ahmed, A. S., Oraby, M. & Abdelshakour, M. A. Two birds with one stone: sustainable smart spectrophotometric methods for concurrent determination of silodosin and mirabegron: application to dosage forms and greenness assessment. BMC Chem. 19, 56 (2025).","journal-title":"BMC Chem."},{"key":"13989_CR13","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.4155\/bio.13.117","volume":"5","author":"YQ Tang","year":"2013","unstructured":"Tang, Y. Q. & Weng, N. Salting-out assisted liquid\u2013liquid extraction for bioanalysis. Bioanalysis 5, 1583\u20131598 (2013).","journal-title":"Bioanalysis"},{"key":"13989_CR14","doi-asserted-by":"publisher","first-page":"100980","DOI":"10.1016\/j.scp.2023.100980","volume":"32","author":"HM Lotfy","year":"2023","unstructured":"Lotfy, H. M., Obaydo, R. H. & Nessim, C. K. Spider chart and whiteness assessment of synergistic spectrophotometric strategy for quantification of triple combination recommended in seasonal influenza\u2013Detection of spurious drug. Sustain. Chem. Pharm. 32, 100980 (2023).","journal-title":"Sustain. Chem. Pharm."},{"key":"13989_CR15","doi-asserted-by":"publisher","first-page":"122715","DOI":"10.1016\/j.saa.2023.122715","volume":"296","author":"IM Nour","year":"2023","unstructured":"Nour, I. M., Mohamed, A. R., Hasan, M. A. & Badrawy, M. Eco-friendly-assessed micellar-fluorimetric platform for concurrent analysis of empagliflozin and Prucalopride succinate in biological fluids: Docking simulation, spectrochim. Acta part A mol. Biomol. Spectrosc. 296, 122715 (2023).","journal-title":"Biomol. Spectrosc."},{"key":"13989_CR16","doi-asserted-by":"publisher","first-page":"19873","DOI":"10.1038\/s41598-024-69518-w","volume":"14","author":"KM Kelani","year":"2024","unstructured":"Kelani, K. M., Said, R. A., El-Dosoky, M. A. & Mohamed, A. R. Innovative voltammetric techniques for Bumadizone analysis in pharmaceutical and biological samples: emphasizing green, white, and blue analytical approaches. Sci. Rep. 14, 19873 (2024).","journal-title":"Sci. Rep."},{"key":"13989_CR17","doi-asserted-by":"publisher","first-page":"116223","DOI":"10.1016\/j.trac.2021.116223","volume":"138","author":"PM Nowak","year":"2021","unstructured":"Nowak, P. M., Wietecha-Pos\u0142uszny, R. & Pawliszyn, J. White analytical chemistry: an approach to reconcile the principles of green analytical chemistry and functionality. TrAC Trends Anal. Chem. 138, 116223 (2021).","journal-title":"TrAC Trends Anal. Chem."},{"key":"13989_CR18","doi-asserted-by":"publisher","first-page":"100976","DOI":"10.1016\/j.scp.2023.100976","volume":"32","author":"RA Sayed","year":"2023","unstructured":"Sayed, R. A., Mohamed, A. R., Shalaby, A. & Ibrahim, H. Earth-friendly-assessed UV-spectrophotometric approaches for concurrent determination of mirabegron and Solifenacin succinate in different matrices. Sustainable Chem. Pharm. 32, 100976 (2023).","journal-title":"Sustainable Chem. Pharm."},{"key":"13989_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/jaoacint\/qsad123","volume":"107","author":"IM Nour","year":"2024","unstructured":"Nour, I. M., Mohamed, A. R. & Badrawy, M. Innovative UV protocols based on straightforward mathematical filtration for concurrent Estimation of two antidiabetic drugs in their brand-new combination: A comparative study. J. AOAC Int. 107, 40\u201345 (2024).","journal-title":"J. AOAC Int."},{"key":"13989_CR20","doi-asserted-by":"publisher","first-page":"123551","DOI":"10.1016\/j.saa.2023.123551","volume":"305","author":"E Darweish","year":"2024","unstructured":"Darweish, E. & Mohamed, A. R. Sustainable UV approaches supported by greenness and whiteness assessments for estimating a recently FDA-approved combination for managing urologic disorders: tukey\u2019s test. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 305, 123551 (2024).","journal-title":"Spectrochim. Acta Part A Mol. Biomol. Spectrosc."},{"key":"13989_CR21","unstructured":"ICH. Q2A (R1. ). Validation of analytical procedures: text and methodology. International Conference on Harmonization. Geneva, Switzerland: IFPMA, (2005)."},{"key":"13989_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/2042098616659412","volume":"7","author":"K Warren","year":"2016","unstructured":"Warren, K., Burden, H. & Abrams, P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety, ther. Adv. Drug Saf. 7, 204\u2013216 (2016).","journal-title":"Adv. Drug Saf."},{"key":"13989_CR23","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/j.clinthera.2009.11.024","volume":"31","author":"S Schilit","year":"2009","unstructured":"Schilit, S. & Benzeroual, K. E. Silodosin: A selective \u03b11A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin. Ther. 31, 2489\u20132502 (2009).","journal-title":"Clin. Ther."},{"key":"13989_CR24","doi-asserted-by":"publisher","first-page":"117435","DOI":"10.1016\/j.trac.2023.117435","volume":"170","author":"MS Eissa","year":"2024","unstructured":"Eissa, M. S. & Darweish, E. Insights on ecological spectroscopic techniques recently adopted for pharmaceutical analysis: A comprehensive review from the perspective of greenness assessment metrics systems application. TRAC Trends Anal. Chem. 170, 117435 (2024).","journal-title":"TRAC Trends Anal. Chem."},{"key":"13989_CR25","doi-asserted-by":"publisher","first-page":"102047","DOI":"10.1016\/j.scp.2025.102047","volume":"46","author":"AR Mohamed","year":"2025","unstructured":"Mohamed, A. R., Darweish, E. & El-Hanboushy, S. Towards greener pharmaceutical quality control: first green UV-based analytical strategies for assaying the newly-introduced candesartan\/chlorthalidone mixture in their pharmaceutical and dissolution medium. Sustain. Chem. Pharm. 46, 102047 (2025).","journal-title":"Sustain. Chem. Pharm."},{"key":"13989_CR26","doi-asserted-by":"publisher","first-page":"112585","DOI":"10.1016\/j.microc.2024.112585","volume":"209","author":"KM Kelani","year":"2025","unstructured":"Kelani, K. M., Essam, H. M., Mohamed, A. R. & Bassuoni, Y. F. A sustainable approach to chromatography: simultaneous determination of paracetamol, methocarbamol, and impurities with a focus on environmental and computational metrics. Microchem J. 209, 112585 (2025).","journal-title":"Microchem J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13989-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:33:16Z","timestamp":1757457196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13989-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13989"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13989-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29829"}}